(Q54248942)

English

Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

Helicobacter pylori

1 reference

based on heuristic

inferred from title

author name string

G J Malanoski

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

G M Eliopoulos

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

M J Ferraro

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

R C Moellering

4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

publication date

1 February 1993

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

European Journal of Clinical Microbiology & Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

12

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

131-133

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

https://scigraph.springernature.com/pub.10.1007/bf01967591

0 references

Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents

1 reference

https://api.crossref.org/works/10.1007%2FBF01967591

21 January 2018

Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin

1 reference

https://api.crossref.org/works/10.1007%2FBF01967591

21 January 2018

Clarithromycin and omeprazole for Helicobacter pylori

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Failure of azythromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of antibiotics in Campylobacter pylori associated peptic ulcer disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Susceptibility of Campylobacter pylori to the newer cephalosporin antibiotics.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spiral organisms in endoscopic biopsies of the human stomach

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8388791

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01967591

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8388791

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54248942&oldid=1388608097"